A retrospective real-world study indicated that treatment with an anti-angiogenic agent (lenvatinib) in combination with an ICI showed a trend towards improved survival in patients with advanced BTCs beyond first line treatment with manageable adverse events 23 .
← all excerpts
Sintilimab and anlotinib with gemcitabine plus cisplatin in advanced biliary tract cancer: SAGC a randomized phase 2 trial.
1
—
—